A line of evidence shows that telomere extension by telomerase leads to cellular immortalization that is characteristic of cancer cells. Recent findings revealed that oncogenes are activated through the inhibition of tumor suppressors and the activation of hTERT promoter following telomere extension. It is thus critical to prevent the activation of telomerase and telomere extension for the suppression of tumorigenesis. This review summarizes the structure of telomere and the mechanism of telomere extension and discusses the molecular targets for the development of novel cancer therapy.
Introduction
Several lines of evidence show that telomere extension is inexorably linked with the immortalization of tumor cells [1, 2] . Normal cells gradually lose a repetitive sequence, d (TTAGGG), in telomeres during the course of mitosis until they stop dividing [3, 4] . In most tumor cells, however, the telomere is regenerated by the action of a nucleoprotein, named telomerase, which prevents tumor cells from undergoing apoptosis [5] . Because the expression of telomerase is frequently induced in tumor cells instead of normal cells, it is very likely that telomere and telomerase extension are neoteric targets for the suppression of tumor development. In order to analyze the action mode of telomere extension, it is necessary to define the structure of telomere and telomerase.
Structure and Function of Telomere and Telomerase
Telomere is a nucleoprotein complex residing in the termini of chromosomes with a repetitive DNA sequence of d (TTAGGG) [6, 7] , which protects the chromosome ends from the recognition by the DNA-damage repair machinery and the enzymatic degradation. Its characteristic is that the length of the telomeric 3'-single strand is longer than that of the 5'-strand. In young human cells, there are 100-200 more repeats of d (TTAGGG) in the 3'-single strand that folds over onto itself to form a unique structure, called T-Loop [8] . Some repeats of the d (TTAGGG) sequence in the 3'-overhang are lost during DNA replication.
Under certain conditions, the 3'-protruded portion forms a complex structure called Gquadruplex, or D-Loop [9] .
Several nucleoproteins are known to interact with the termini of the teromeric structure. In human, six kinds of proteins bind to the teromeric termini to form a complex named shelterin that consists of the telomeric repeat-binding factor 1 (TRF1), TRF2, the TRP1 and TRP2-interacting nuclear protein 2 (TIN2), the protection of telomeres 1 (POT1), the adenocortical dysplasia protein homolog (TPP1), and the repressor/activator protein 1 (RAP1) [10] . Since it is demonstrated that the down-regulation of POT1 and TRF1 leads to the inhibition of tumor cell growth [11, 12] , there is a close link between the shelterin complex and the mechanism underlying telomere extension [13] , suggesting that the shelterin complex is a promising target for cancer therapy.
TRF1 plays a unique role in the shelterin complex during telomere extension. TRF1, highly expressed in adult stem cells and many tumor cells, interacts with the end of telomeric dsDNA. It is reported that TRF1 could regulate mitosis and affect the despiralization and replication of telomeric DNA [13, 14] . The over expression of TRF1 results in the diminish of telomeric DNA and the inhibition of the protein binding to telomere which leads to elongation of telomeric repeats in tumor cells [15, 16] . In fact, the length of telomere becomes short when TRF1 binds to teromeric DNA, suggesting that TRF1 is a factor that controls the telomere length by inhibiting the activity of telomerase [17] . Telomere is comprised of a repetitive sequence of TTAGGG, containing a long dsDNA region (left) and a smaller single G-rich 3'-overhang (right). The shelterin complex includes six kinds of proteins (TRF1, TRF2, TPP1, POT1, TIN1 and RAP1). TRF1 binds to the terminus of the double-stranded telomeric DNA, and prevents telomere from mutation, resulting in the stabilization of telomeric structure.
POT1 tightly binds to the single-stranded G-rich DNA extensions at the ends of chromosomes and interacts with TPP1, resulting in the regulation of the 3'-overhang length and the stabilization of telomeres [18] [19] . Though most mammalian cells have a single POT1 gene, the cells of mice have two distinct POT1 paralogs, POT1a and POT1b. POT1a protects the ends of the chromosomes from an ATR-dependent DNA damage repsonse and POT1b regulates telomerase-mediated telomere extension [20, 21] . Although it is not known whether POT1a and POT1b are present in the same shelterin complex or in the two distinct complexes, the expression levels of these proteins are almost equal and both factors are required for the full protection of chromosomes based on a mouse gene-deletion model. It is thus most likely that POT1 is a promising target for cancer therapy. Besides telomeric shelterin, telomerase plays an essential role in the protection of telomeric end of chromosomes, because it is highly expressed in many tumor cells [22, 23] . Telomerase itself is a RNA-protein complex consisting of RNA, hTERT and other protein subunits and catalyzes the extension of telomeres during mitosis. It is shown that the induction of hTERT, a core part of telomerase, is essential and sufficient for the telomerase activity in cells and that the activation of telomerase is an important step in the acquisition of the immortalization for tumor cells [24, 25] . If the expression of hTERT can be regulated by small molecules, it may open a promising strategy to control the progression of tumors.
Factors that Affect hTERT Promoter
Whereas much attention has been paid to transcription factors that interact with and control the hTERT promoter, the precise mechanism underlying the regulation of hTERT expression has not been fully delineated yet. In this section, transcription factors so far suggested to be involved in the hTERT regulation are reviewed. Possible regulation factors and their upstream factors involved in the hTRET expression are depicted.
c-Myc
The c-Myc oncogenic protein is a pivotal transcription element that influences more than 15% of all genes. The c-Myc target genes are involved in many facets of the cellular behavior including cell growth, differentiation, apoptosis and multiplication [26] . Under physiological conditions, c-Myc is expressed during multiplication and chromosome translocation. In addition to such physiological functions, c-Myc plays pivotal roles in tumorigenesis. In fact, the proto-oncogene is estimated to be involved in 20% of all human cancers, including lung cancer, gastric cancer and breast cancer. The high expression of cMyc is observed in most B-cell lymphomas that c-Myc locus is rearranged.
The over-expression of c-Myc in tumor cells directly leads to the up-regulation of hTERT mRNA transcription, resulting in the activation of telomerase and cellular immortalization. Thus, the inhibition of the hTERT transcription is also a promising approach of c-myc-induced tumorigenesis [27, 28] . In addition, c-Myc controls the transcription of E2F1 that is an important transcription factor involved in the cellular migration and multiplication and represses the transcription of hTERT [29.30] . It is therefore likely that not only hTERT, but also E2F1 is an ideal target for the development of anti-tumor drugs.
TGF-β Signaling
It was first pointed out that telomerase activity is significantly reduced by TGF-β that is involved in cell growth, cytokine expression and the inhibition of lymphocyte differentiation [31] . Later, it was found that TGF-β regulates Smad3, resulting in the repression of c-myc gene, which in turn down-modulates the expression of hTERT and suppresses the telomerase activity [32] . Furthermore, it was shown that TGF-β also tranduces signals through an alternative pathway and up-regulates the expression of mitogen activated protein kinase (MAPK), resulting in the activation of the cell cycle inhibitiors p15 and p21, the inhibition of the transcription of hTERT and the suppression of telomerase activity [33, 34] . It is thus the TGF-β pathway is also a promising target for the development of cancer therapy.
E6
It was initially found that human papilloma virus type 16 (HPV-16) E6 protein activates telomerase in early-passage human keratinocytes and mammary epithelial cells. This activation occurred in cells pre-crisis. Studies using HPV-16 E6 mutants demonstrated that the activation of telomerase by E6 gene product is not mediated by p53 [35] . It was then shown that HPV-16 E6 protein interacts with GC-rich SP1 bound to hTERT promoter and up-regulates the telomere activity, resulting in the induction of cell immortalization [36] . In addition, HPV-16 E6 protein regulates the expression of c-Myc gene and induces tumorigenesis. It was confirmed that telomerase activity could not be induced when both Myc and Sp1 binding sites were mutanted [37] . Furthermore, other molecules, such as NF-κB, Mad1 and MEN1, are also involved in the activation of telomerase through the expression of hTERT.
Biological Significance of TRF1
TRF1 is the first sheltrin component protein discovered in 1995. It was shown to bind to the termini of chromosomes and to regulate the length of telomere and cell cycle. The mode of interaction between TRF1 and telomeric DNA is very dynamic and the exchange rate of bound TRF1 and free TRF1 is very high. The physiological function of the protein is shown to be diverse.
AKT-mediated Phosphorylation of TRF1
Akt, also known as protein kinase B (PKB), is a serine/threonine-specific kinase with a molecular weight of 60kDa that plays a pivotal role in multiple cellular processes such as cytokines expression, glucose metabolism, cell proliferation, transcription, cell migration, apoptosis and oncogene Ras activation. In 2009, it was demonstrated that the overexpression of Akt decreased the length of telomere and Akt interacted with TRF1. Because threonine 273 is phosphorylated in in vitro kinase assay, Akt is thought to regulate the function of TRF1 and the genomic instability as well as tumorigenesis [38] .
Phosphorilation of TRF1 by Cdk1
Cyclin B-dependent kinase 1 (Cdk1) is key regulator of mitotic entry and is shown to interact with serine/threonine phosphorylation sites of TRF1, including S11, T149, T344 and T371 [39, 40] . It is demonstrated that Pin1, a prolyl isomerase, regulates the conformation and function of TRF1 and that a Cdk1 inhibitor interferes with the interaction between TRF1 and Pin1, suggesting that Cdk1 regulates telomere maintenance. Mutation analysis indicates that Cdk1 phosphorlates T149 of TRF1 and facilitates the interaction between TRF1 and Pin1.
When Cdk1 phosphorylates T371 of TRF1, TRF1 fails to bind to the ends of chromosomes in early mitosis. This phosphorylation leads to the loss of telomere-bound TRF1 and TIN2 as well as an accumulation of damage response factors such as γ-H2AX, a cellular factor signifying DNA in response to damage [41] . Consistent with the finding, a phosphomimic mutation of T371 prevents the interaction between TRF1 and telomeric DNA and causes telomere instability [42] . By contrast, the non-phosphomimic mutation leads to a tight interaction between TRF1 and telomeric DNA. Thus, TRF1 plays an essential role in the maintenance of telomere integrity.
In vivo effect of TRF1-deletion on Tumorigenesis
So far, it has been shown that TRF1 is closely associated with telomere maintenance in normal cells as well as tumor cells and can thus be a promising target for anti-tumor therapy. In p53-dificient mice, for instance, TRF1-deletion impairs cellular immortalization and up-regulates the expression of oncogene k-Ras G12v . The up-regulation K-Ras by TRF1 deletion leads to telomeric DNA damage and apoptosis under the condition where p53 is abrogated. It is characteristic that TRF1 deletion results in the accumulation of γ-H2AX at telomeric DNA, leading to the instability of chromosomes [43, 44] . In addition, TRF1 deficiency results in lower cellular multiplication, increasing G2 arrest and mitotic inactivity [45] . It is further demonstrated that TRF1 abraogation inhibits the growth of aggressive lung carcinomas independently of telomere length and p53 status [45] .
The interaction between TRF1 and telomeric DNA in normal cells enhances the stabilization of telomeric structure and prevent the chromosomal ends from being recognized by DNA damage machinery. Although the effect of TRF1 inhibition on normal cells remains to be extensively examined, the deletion of TRF results in evident anti-tumor effect in vivo. TRF1 is thus a promising target for the development of anti-tumor therapeutics.
G-quadruplex as a Therapeutic Target for Cancer Therapy
Telomeric DNA can be divided into two structurally distinct regions, the double-stranded telomeric DNA and the single-stranded telomeric 3'-overhang. In the presence of cations, the telomeric 3'-overhang can be transformed into G-quadruplex, a structurally defined secondary structure of DNA making up with a guanine-rich sequence, which can inhibit human telomerase activity and thus telomere extension [46] . Four guanine bases associate through hydrogen bonding to form a square planar structure called guanine-tetrad (G-tetrad) . Two or more G-tetrads stack on top of each other to form a special DNA secondary structure, G-quadruplex. The G-quadruplex structure is further stabilized by the presence of cations like potassium that are embeded into the interspace between G-tetrads with high affinity through π-πstacking mode.
Our unpublished data show that a combination of a structurally defined planar molecules and cations can firmly inlay between G-tetrads of G-quadruplex with high affinity through π-π stacking mode (Fig 4. ) [47, 48] . In addition to guanine, adenine has stronger affinity to the planar molecules, as compared with thymine, because adenine contains a conjugateforming basic group that can preferentially form a complex structure where PI electrons are shared with embedded molecules (Fig 5. ). The affinity of the interaction between basic group A and a planar molecule is high when compared with T, because A preferentially forms a complex structure with the embedded planar molecule through π-π stacking mode. The planar molecule thus intrudes into the space between basic group A and G-tetrad of the telomeric G-quadruplex.
Although the G-quadruplex is considered to be functionally important in transcriptional regulation, the existence of such a structure has not been identified using an ordinary analytical method. Recently, it was reported that the G-quadruplex structures are present in mammalian genomes and the nature and distribution of the complex structures were identified using a G-quadruplex-specific probes [49, 50] . It is thus likely that certain small compounds that facilitate the formation and stability of the G-quadruplex structures can inhibit the telomerase activity as well as the proliferation of tumor cells. These findings encourage medicinal chemists to proceed a research to identify small compounds that inhibit tumor progression.
Conclusion
Ectopic telomeric extension deregulates the cell cycle machinery and eventually leads to cell immortalization. In normal cells, telomeric DNA loses some parts of d (TTAGGG) repeats during mitosis because telomerase is not induced. By contrast, telomerase is highly expressed in many cancer cells, in which hTERT is abberantly induced. hTERT is the catalytic subunit of telomerase and the induction of the protein is one of the most characteristic events in tumor cells [25, 26] . hTERT promoter is, therefore, a key target to develop a novel therapeutic for cancer therapy.
In addition to the suppression of telomerase activity by regulating hTERT promoter, it is also promising to find a means to suppress the function of TRF1 for the development of cancer therapy. It is demonstrated that the protein stabilizes sister chromosomes as TRF1-deletion induces telomeric DNA damage and apoptosis. In addition, TRF1-deletion impairs the growth of lung carcinomas which is accompanied by induction of telomeric DNA damage, apoptosis, decreased proliferation, and G2 arrest, suggesting that TRF1 is an ideal target for cancer therapy.
Furthermore, the inhibition of telomere function by stabilizing G-quadruplex structure in genomes is another strategy for cancer therapy. In fact, it has been reported small molecules stabilize G-quadruplex complexes and inhibit maintenance and translation of telomeric DNA [53, 54] . Based on these findings, many laboratories have explored small compounds that could promote the formation and stabilization of G-quadruplex complexes and exhibit beneficial effects in the therapy of cancer. As compared with currently available chemotherapy, molecules that stabilize the formation of G-quadruplex complexes are likely to be more specific and thus cause few adverse events.
The development and progression of cancer are a complex process and influenced by many cellular factors such as nuclear proteins and chromosome structures as well as other cellular microenviroment. Nevertheless, many cancer cells can limitlessly extend the length of telomere DNA. It is thus important to find a strategy to effecttively control the telomeric transcription and expressionfor the development of anti-cancer therapeutics. Although the mechanism underlying the cancer development is complex, it is a promising strategy for the establishment of a novel cancer therapy to focus on the cellular mechanism for the maintenance of telomere, the integrity of shelterin, and the stability of G-quadruplex structure [49] .
